Intro
Foreword
Contents
About the Editors
1: Ferroptosis: Concepts and Definitions
References
2: Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors
2.1 Pancreatic Cancer Therapeutic Challenges
2.2 Ferroptosis and PDAC
2.2.1 xCT-Based Ferroptosis Inducers as Systemic Therapeutics for PDAC
2.2.2 xCT-Based Early Detection of Metastasized PDAC
2.3 Metabolic Status Dictates Sensitivity Toward Ferroptosis
2.4 Promoting Ferroptosis and Antigenicity in PDAC

2.5 How Stromal Compartment Influences Sensitivity to Ferroptosis
2.6 Concluding Remarks
References
3: Iron Homeostasis and Metabolism: Two Sides of a Coin
3.1 Iron in Physiology and Disease
3.1.1 Iron: Origin, Chemical Properties and Evolution
3.1.2 Insights into the Redox Chemistry of Iron
3.1.3 Strategies for Iron Assimilation and Transport
3.2 Concluding Remarks
References
4: The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis
4.1 Introduction
4.2 NCOA4-Mediated Ferritinophagy
4.3 NCOA4-Mediated Ferritinophagy and Ferroptosis

4.4 Ferritinophagy and Ferroptosis in Cancer
4.5 Ferritinophagy and Ferroptosis in Neurodegeneration
4.5.1 Neuroferritinopathy
4.5.2 Alzheimer's Disease
4.5.3 Parkinson's Disease
4.5.4 Huntington's Disease
4.5.5 Amyotrophic Lateral Sclerosis
4.5.6 Brain Injury
4.6 Conclusions and Future Directions
References
5: Emerging Role for Ferroptosis in Infectious Diseases
5.1 Introduction
5.2 Necrosis in Infectious Diseases
5.2.1 Pyroptosis and Necroptosis in Infectious Diseases
5.3 Ferroptosis in Infectious Diseases

5.3.1 Pathogen-Induced Ferroptotic Cell Death
5.3.1.1 Bacterial Infections
Salmonella Typhimurium Infection
Mycobacterium tuberculosis Infection
Pseudomonas aeruginosa Infection
Polymicrobial Sepsis
5.3.1.2 Viral Infection
5.3.1.3 Parasitic Infection
5.4 Concluding Remarks
References
6: Small Molecule Regulators of Ferroptosis
6.1 Introduction
6.2 Activators of Ferroptosis
6.2.1 Targeting GPX4 Activity and Lipid Production
6.2.1.1 Deficiency of GPX4 Production (Scheme 6.1
Fig. 6.2)
6.2.1.2 Boost of Lipid Production (Scheme 6.1

Fig. 6.3)
6.2.2 GSH Depletion and Nuclear Factor (Erythroid-Derived 2)-like 2 (NrF2) Inhibition
6.2.2.1 System Xc- Inhibition (Scheme 6.1
Fig. 6.4)
6.2.2.2 Alteration of GSH Metabolism (Scheme 6.1
Fig. 6.5)
6.2.2.3 NrF2 Inhibition (Scheme 6.1
Fig. 6.6)
6.2.3 Iron and ROS Production
6.2.3.1 Labile iron Pool Enrichment (Scheme 6.2
Fig. 6.7)
6.2.3.2 Inducing ROS (Scheme 6.2
Fig. 6.9)
6.2.3.3 A Small molecule Inducer of Membrane Leakage (Scheme 6.2
Fig. 6.10)
6.3 Inhibitors of Ferroptosis